Literature DB >> 30030719

A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST).

Xuechao Liu1,2, Haibo Qiu1,2, Zhiming Wu1,3, Peng Zhang4, Xingyu Feng5, Tao Chen6, Yong Li5, Kaixiong Tao4, Guoxin Li6, Xiaowei Sun7,8, Zhiwei Zhou9,10.   

Abstract

BACKGROUND: To determine the better risk stratification based on surgical pathology and to assess the clinical outcomes after curative resection with a new scoring system in high risk gastrointestinal stromal tumor (GIST) patients.
METHODS: We retrospectively evaluated 506 high-risk GIST patients who underwent curative resection as initial treatment at four centers from 2001 to 2015.
RESULTS: Multivariate analysis revealed that only Ki-67 labeling index (LI) and mitotic index were independent prognostic factors of overall survival (OS). For the two tumor-related pathological factors, Ki-67 LI > 7% and mitotic index ≥ 7/50 high power fields were allocated 1 point each. The total score was defined as the Pathological Prognostic Score (PPS). When Ki-67 LI and mitotic index were replaced by PPS, a multivariate analysis still identified PPS as an independent predictor of OS (HR 2.719; 95% CI 1.309-5.650; P = 0.007). Patients with a PPS of 0, 1, or 2 had a 5-year survival of 91.8, 79.8, and 51.0%, respectively (P = 0.001). Furthermore, an elevated PPS (PPS = 2) was associated with larger tumor size, non-stomach tumor, and open resection (all P < 0.05).
CONCLUSION: The PPS independently predicted postoperative survival in high-risk GIST, and it might facilitate the selection of appropriate treatment strategy for these patients.

Entities:  

Keywords:  Gastrointestinal stromal tumor; Ki-67 labeling index; Mitotic index; Pathological prognostic score; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30030719     DOI: 10.1007/s11605-018-3799-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  34 in total

1.  Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

Authors:  Lorenzo D'Ambrosio; Erica Palesandro; Paola Boccone; Francesco Tolomeo; Sara Miano; Danilo Galizia; Antonio Manca; Gabriele Chiara; Ilaria Bertotto; Filippo Russo; Delia Campanella; Tiziana Venesio; Dario Sangiolo; Ymera Pignochino; Dimitrios Siatis; Michele De Simone; Alessandro Ferrero; Alberto Pisacane; Angelo Paolo Dei Tos; Sandra Aliberti; Massimo Aglietta; Giovanni Grignani
Journal:  Eur J Cancer       Date:  2017-04-24       Impact factor: 9.162

Review 2.  Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.

Authors:  Burton L Eisenberg; Jonathan C Trent
Journal:  Int J Cancer       Date:  2011-12-01       Impact factor: 7.396

3.  Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors.

Authors:  Borislav Belev; Iva Brčić; Juraj Prejac; Zrna Antunac Golubić; Damir Vrbanec; Jadranka Božikov; Ivan Alerić; Marko Boban; Jasminka Jakić Razumović
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

4.  Telomerase activity in gastrointestinal stromal tumors.

Authors:  S Sakurai; M Fukayama; Y Kaizaki; K Saito; K Kanazawa; M Kitamura; Y Iwasaki; T Hishima; Y Hayashi; M Koike
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

5.  Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors.

Authors:  Eckhard Klieser; Maximilian Pichelstorfer; Denis Weyland; Ralf Kemmerling; Stefan Swierczynski; Adam Dinnewitzer; Tarkan Jäger; Tobias Kiesslich; Daniel Neureiter; Romana Illig
Journal:  Mol Clin Oncol       Date:  2016-03-11

6.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 8.  Adjuvant therapy in primary GIST: state-of-the-art.

Authors:  P Reichardt; J-Y Blay; I Boukovinas; T Brodowicz; J M Broto; P G Casali; M Decatris; M Eriksson; H Gelderblom; P Kosmidis; A Le Cesne; A L Pousa; M Schlemmer; J Verweij; H Joensuu
Journal:  Ann Oncol       Date:  2012-07-25       Impact factor: 32.976

Review 9.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Authors:  J Lasota; M Miettinen
Journal:  Histopathology       Date:  2008-02-28       Impact factor: 5.087

10.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

Authors:  Heikki Joensuu
Journal:  Hum Pathol       Date:  2008-10       Impact factor: 3.466

View more
  5 in total

Review 1.  Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe.

Authors:  Lin Tu; Peter Hohenberger; Heike Allgayer; Hui Cao
Journal:  Visc Med       Date:  2018-10-19

2.  Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.

Authors:  Yao Lin; Ming Wang; Jie Jia; Wenze Wan; Tao Wang; Wenchang Yang; Chengguo Li; Xin Chen; Hui Cao; Peng Zhang; Kaixiong Tao
Journal:  EBioMedicine       Date:  2020-09-25       Impact factor: 8.143

3.  Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.

Authors:  Ruolin Liu; Yingxin Wu; Jin Gong; Rui Zhao; Li Li; Qianyi Wan; Nan Lian; Xiaoding Shen; Lin Xia; Yuhou Shen; Haitao Xiao; Xiaoting Wu; Yi Chen; Ying Cen; Xuewen Xu
Journal:  Cancer Med       Date:  2022-03-16       Impact factor: 4.711

4.  Associations of CD34, Ki67, layer of invasion and clinical pathological characteristics, prognosis outcomes in gastrointestinal stromal tumors-a retrospective cohort study.

Authors:  Jianqi Yang; Enming Xing; Xian Zhang; Wenmiao Cao; Yichen Liang
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

5.  Increased ski expression levels are associated with a higher risk and poor prognosis in patients with gastrointestinal stromal tumors.

Authors:  Qiu-Shi Wang; Yu Zhai; Ping Li; Hua-Liang Xiao; Yuan-Guo Zhou
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.